Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8101149 | 0.90 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL23770526 | 0.89 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL8129805 | 0.81 | SIGMAR1 (0.58) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17203091 | 0.81 | KDM1A (0.40) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL11937070 | 0.79 | SIGMAR1 (0.57) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL2743258 | 0.76 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL14112074 | 0.75 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL11937068 | 0.73 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL21788652 | 0.73 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7379764 | 0.73 | SIGMAR1 (0.64) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-06-02 | — | — | US | disclosed |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | ENTPD5, ENTPD1, NT5E | SIGMAR1 4584/4885ALDH1A1 205/4885TP53 1079/4885 |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | ENTPD5, ENTPD1, NT5E | SIGMAR1 4584/4885ALDH1A1 205/4885TP53 1079/4885 |
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BTK, LYN, LCK | SIGMAR1 4429/4885ALDH1A1 4695/4885TP53 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.